# Indapta Therapeutics

Source: https://onco.cc/companies/indapta-therapeutics/  
OnCo record `indapta-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Indapta Therapeutics, of Houston, makes IDP-023, an off-the-shelf natural killer cell therapy from donor g-NK cells, a subset that lacks the FcR gamma chain, and tests it alongside antibody drugs in myeloma and non-Hodgkin lymphoma and in progressive multiple sclerosis. The FDA granted Fast Track status in 2024, and efficacy data are still early.

## Summary

Indapta Therapeutics is developing IDP-023, a proprietary, off-the-shelf allogeneic FcR gamma-deficient natural killer (g-NK) cell therapy for cancer and autoimmune disease. According to release titles on the company site, the first patients were treated with IDP-023 in January 2024, the FDA granted Fast Track designation for non-Hodgkin lymphoma and myeloma in February 2024, the company received a $4.5 million CPRIT award in May 2024, an IND for progressive multiple sclerosis was cleared in August 2024, a clinical study collaboration with Sanofi in multiple myeloma was announced in December 2024, and clinical activity in relapsed or refractory multiple myeloma was presented in November 2025. SEC Form D filings list the company in Houston, Texas, with about $33.6 million of equity sold in early 2022 and about $50.8 million sold in an offering that began in September 2025.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Houston, TX
- Type: cell-therapy
- Website: https://indapta.com/

## Notes

- The user's hint says San Francisco; Form D filings give Houston, TX. Programme milestones are taken from press-release titles linked on the homepage (the Business Wire pages themselves returned 403). The g-NK product is not CAR-engineered; 'car-nk-macrophage' is the closest available id. The December 2024 $22.5 million financing release could not be fetched.

## Sources

- Official website: https://indapta.com/
- Form D, October 2025: https://www.sec.gov/Archives/edgar/data/1910175/000191017525000003/primary_doc.xml
- Form D, February 2022: https://www.sec.gov/Archives/edgar/data/1910175/000191017522000001/primary_doc.xml

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)
- technologies: [Allogeneic (off-the-shelf) cell therapy](https://onco.cc/technologies/allogeneic-cell-therapy/), [CAR-NK & CAR-macrophage](https://onco.cc/technologies/car-nk-macrophage/)
- trials: [IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers](https://onco.cc/trials/nct06119685/)

---
JSON: https://onco.cc/api/v1/entities/indapta-therapeutics.json